Rodman & Renshaw Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $17
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Mira Pharmaceuticals with a Buy rating and set a price target of $17.
September 30, 2024 | 4:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Mira Pharmaceuticals with a Buy rating and a price target of $17, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $17 by Rodman & Renshaw suggests a positive sentiment towards Mira Pharmaceuticals. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100